# OnCo record nct05623319 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05623319/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05623319", "NCT05623319" ;
  schema:name "Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)"@en ;
  schema:alternateName "THOR"@en ;
  schema:description "A phase 2 trial of pembrolizumab and olaparib in lung cancer, run by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05623319/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05623319> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/extensive-stage-sclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/parp-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/olaparib/> .